Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regenerative Medicine In Cures: Conditional Approval Dropped In Lieu Of ‘Breakthrough’-Style Approach

Executive Summary

Push to open up new US pathway for regenerative medicine helped the 21st Century Cures bill make it to the finish line in the lame duck Congress – but only after the proposal has been dramatically revised to fit into the established BLA pathway.

Advertisement

Related Content

Will US FDA User Fee Reauthorization Bring More RATS?
US FDA's Authority Over CRISPR Is Adequate, NASEM Finds, But Off-Label Challenge May Emerge
RAT Race Begins: FDA Accepting Regenerative Advanced Therapy Designation Requests
The Unlikely Savior Of 21st Century Cures: Donald Trump
The Unlikely Savior Of ‘21st Century Cures’ Is Donald Trump
US FDA Getting More Money Up Front Under Cures Bill Revisions
NIH Funding Component of 21st Century Cures May Get White House Boost
Regulating Cell Therapies: Conditional Approval Under Consideration In Congress; FDA Plans Public Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS119604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel